Patents by Inventor Charles Allerson

Charles Allerson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8394947
    Abstract: The present invention provides oligomeric compounds having sufficient complementarity to hybridize to a nucleic acid target and methods for their use in modulating gene expression. In one embodiment the oligomeric compounds comprise double stranded constructs wherein one of the strands capable of hybridizing to a nucleic acid target, and has a plurality of modified ribofuranosyl nucleosides at defined locations. The presence of modifications at such defined positions greatly enhances the properties of the corresponding compositions.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: March 12, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Eric E. Swayze, Thazha P. Prakash, Charles Allerson, Prasad Dande, Richard H. Griffey
  • Publication number: 20130041011
    Abstract: Provided herein are novel base modified bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel pyrimidine bicyclic nucleosides are provided wherein each pyrimidine base is substituted at the 5 position with an optionally substituted, aromatic or heteroaromatic ring system comprising from 5 to 7 ring atoms selected from C, N, O and S. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: January 6, 2011
    Publication date: February 14, 2013
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Charles Allerson, Balkrishen Bhat, Eric E. Swayze
  • Publication number: 20130041144
    Abstract: Provided herein are novel 5?-(S)—CH3 substituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the furanose ring of each of the novel 5?-(S)—CH3 substituted bicyclic nucleosides includes a 2? to 4? bridging group. The 5?-(S)—CH3 substituted bicyclic nucleosides are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as for example increasing the binding affinity. In certain embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: March 10, 2011
    Publication date: February 14, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Michael T. Migawa, Thazha P. Prakash, Charles Allerson, Balkrishen Bhat, Punit P. Seth, Eric E. Swayze
  • Publication number: 20130035369
    Abstract: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes.
    Type: Application
    Filed: August 3, 2012
    Publication date: February 7, 2013
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Eric G. Marcusson, Eric E. Swayze
  • Publication number: 20120071645
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: December 1, 2011
    Publication date: March 22, 2012
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Punit P. Seth
  • Patent number: 8124745
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modification comprising a polycyclic sugar surrogate. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleoside of the oligomer has a polycyclic sugar surrogate modification.
    Type: Grant
    Filed: May 5, 2010
    Date of Patent: February 28, 2012
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: Charles Allerson, Balkrishen Bhat, Eric E. Swayze, Thazha P. Prakash
  • Publication number: 20120021515
    Abstract: The present invention provides oligomeric compounds and uses thereof. In certain embodiments, such oligomeric compounds are useful as antisense compounds. Certain such antisense compounds are useful as RNase H antisense compounds, as RNAi compounds, and/or as modulators of splicing.
    Type: Application
    Filed: February 5, 2010
    Publication date: January 26, 2012
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Punit P. Seth
  • Patent number: 8088904
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: January 3, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Punit P. Seth
  • Patent number: 7939677
    Abstract: The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification.
    Type: Grant
    Filed: August 31, 2010
    Date of Patent: May 10, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Prasad Dande, Thazha P. Prakash, Charles Allerson, Eric E. Swayze, Richard H. Griffey
  • Publication number: 20110046206
    Abstract: The present invention provides double stranded compositions wherein the first strand is modified to have a particular motif and the second strand is modified a selected motif. The motifs are defined by positioning of differentially modified nucleosides wherein at least the sugar moieties are different. More particularly, the present compositions comprise an antisense strand that is modified to have a positional/full motif and the sense strand is modified to have an alternating motif, a hemimer motif, a blockmer motif, a gapped motif, a positional motif, a positional/full motif or a fully modified motif. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: June 23, 2008
    Publication date: February 24, 2011
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Eric G. Marcusson, Eric E. Swayze
  • Patent number: 7875733
    Abstract: The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: January 25, 2011
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Prasad Dande, Thazha P. Prakash, Charles Allerson, Eric E. Swayze, Richard H. Griffey
  • Publication number: 20100324277
    Abstract: The present invention provides modified oligomeric compounds and compositions of oligomeric compounds for use in the RNA interference pathway of gene modulation. The modified oligomeric compounds include siRNA and asRNA having at least one affinity modification.
    Type: Application
    Filed: August 31, 2010
    Publication date: December 23, 2010
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Prasad Dande, Thazha P. Prakash, Charles Allerson, Eric E. Swayze, Richard H. Griffey
  • Publication number: 20100216982
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modification comprising a polycyclic sugar surrogate. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleoside of the oligomer has a polycyclic sugar surrogate modification.
    Type: Application
    Filed: May 5, 2010
    Publication date: August 26, 2010
    Applicant: Isis Pharmaceutiacls, Inc.
    Inventors: Charles Allerson, Balkrishen Bhat, Eric E. Swayze, Thazha P. Prakash
  • Patent number: 7696345
    Abstract: Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modification comprising a polycyclic sugar surrogate. Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex (RISC), wherein at least one nucleoside of the oligomer has a polycyclic sugar surrogate modification.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: April 13, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Charles Allerson, Balkrishen Bhat, Eric E. Swayze, Thazha P. Prakash
  • Publication number: 20090306178
    Abstract: The present invention provides conjugated double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and/or sugar modified nucleosides. More particularly, the present compositions comprise a linked conjugate group on one strand and a non hybridizing region of 2?-modified nucleosides on the other strand. Each strand further comprises one or more phosphorothioate internucleoside linkage. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: March 27, 2007
    Publication date: December 10, 2009
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Garth A. Kinberger, Richard H. Griffey, Eric E. Swayze
  • Publication number: 20090203132
    Abstract: The present invention provides pyrrolidinyl compounds that are useful for preparing conjugated oligomeric compounds. The conjugated pyrrolidinyl compounds can be attached to support medium and provide a free hydroxyl for oligomer synthesis to prepare an oligmeric compound having a 3?-conjugate. Alternatively, the pyrrolidinyl compound can be prepared as a phosphoramidite which can be placed internally or at the 5?-position of an oligomeric compound. These two strategies can be used together to prepare oligomeric compounds having 2 or more conjugates at any selected positions. The present invention also provides methods for modulating gene expression using the conjugated oligomeric compounds.
    Type: Application
    Filed: September 1, 2005
    Publication date: August 13, 2009
    Inventors: Eric E. Swayze, Dale E. Robinson, JR., Elizabeth Anne Jefferson, Prasad Dande, Thazha P. Prakash, Charles Allerson, Balkrishen Bhat
  • Patent number: 7569686
    Abstract: The present invention provides compounds and methods of using them for preparing bicyclic nucleosides. The bicyclic nucleosides are useful for preparing chemically modified oligomeric compounds. Oligomeric compounds comprising these bicyclic nucleosides have enhanced properties such as increased nuclease resistance.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: August 4, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Balkrishen Bhat, Jie Xia, Punit P. Seth, Guillermo Vasquez, Michael T. Migawa, Charles Allerson, Thazha P. Prakash, Eric E. Swayze
  • Publication number: 20090092981
    Abstract: The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Application
    Filed: August 15, 2008
    Publication date: April 9, 2009
    Inventors: Eric E. Swayze, Andrew M. Siwkowski, Balkrishen Bhat, Thazha P. Prakash, Charles Allerson, Punit P. Seth
  • Publication number: 20090048192
    Abstract: The present invention provides double stranded compositions wherein each strand is modified to have a motif defined by positioning of ?-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having an alternating motif and another strand having a hemimer motif, a blockmer motif, a fully modified motif or a positionally modified motif. At least one of the strands has complementarity to a nucleic acid target. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In preferred embodiments the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. The present invention also provides methods for modulating gene expression.
    Type: Application
    Filed: June 2, 2005
    Publication date: February 19, 2009
    Applicant: ISIS PHARMACEUTICALS, INC.
    Inventors: Balkrishen Bhat, Thazha P. Prakash, Prasad Dande, Charles Allerson, Richard H. Griffey, Eric E. Swayze
  • Publication number: 20080261904
    Abstract: The present invention provides double stranded compositions wherein the first strand comprises three different regions and the second strand is native RNA. Each region has native or modified ribofuranosyl sugar moieties that are different than those of the other two regions. At least a portion of the first oligomeric compound is complementary to and hybridizes to a nucleic acid target. The present invention also provides methods for modulating gene expression using the modified oligomeric compounds and compositions of oligomeric compounds.
    Type: Application
    Filed: June 3, 2004
    Publication date: October 23, 2008
    Inventors: Balkrishen Bhat, Eric E. Swayze, Charles Allerson, Prasad Dande, Thazha P. Prakash, Richard H. Griffey